Procter & Gamble is a hold. The company demonstrates steady, low-single-digit revenue growth and expanding operating margins, with operating income rising from $18.5B in FY2024 to $20.5B in FY2025. However, the stock trades below both its 50-day and 200-day moving averages with a neutral RSI of 46, suggesting a lack of positive momentum. While valuation on an EV/EBITDA basis is attractive relative to peers, the price-to-sales multiple is significantly elevated, indicating the market is already pricing in a premium for its defensive characteristics.
Pricing Power Erosion
Recent news highlights cautious shoppers testing demand, which could pressure the pricing strategy that has driven recent revenue growth, potentially compressing margins.
Free Cash Flow Decline
Free cash flow dropped from $16.5B in FY2024 to $14.0B in FY2025, driven by a decrease in operating cash flow and higher capital expenditures, which could limit dividend growth or share buybacks.
Insider Selling
A significant sale by the CEO of Baby, Fem & Family Care in February 2026 at $165.29 per share, well above the current price, may signal concern about near-term business performance or valuation.
Elevated Price-to-Sales Multiple
PG's P/S ratio of 3.9x is 76% above the peer median of 2.2x, making the stock vulnerable to multiple compression if growth disappoints.